ARTICLE | Clinical News
Ivax Phase II Paxoral results
October 22, 2001 7:00 AM UTC
IVX said its Paxoral oral paclitaxel was safe in a European Phase II study of 26 advanced non-small cell lung cancer patients. Paxoral also showed a survival time response rate consistent with single ...